biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Can I ask, Pof?

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jan 23, 2023 5:29am

104 Views

Post# 35239138

RE:Can I ask, Pof?

"I have never seen you like this? Why?"

Midatech's CEO boldly and confidently stated that he defies anyone to find a company of Biodexa's size with the same opportunity set. Let that sink in. I doubt anyone has ever seen him like this. He is in the catbird seat when it comes to understanding where the immense potential of Q-Sphera and Midatech's lead clinical assets are. The largest healthcare company in the world, J&J, is also investigating Q-Sphera and Midatech believes a deal may be near. Midatech believes so much in the future of its technology that it wants to develop opportunities internally as a therapeutics company and has convinced Saltarelli, Ladenberg Thalmann and Armistice Capital to go along.That is a nice consensus.

Saltarelli is in a catbird seat when it comes to understanding xB3. He has stayed with xB3 over a period of years despite having the opportunity to go elsewhere given his resume. He has said xB3 should perform equal to or better than Denali. He is on Chiesi's xB3 Advisory Board. BTI switched its strategic focus to Lysosomal Storage Disorders, inflammation, and neurodegeneration and its lead xB3 asset to Hunter displaying a willingness to go head-to-head against Denali. Denali has a lead of years in Lysosomal Storage and has validated the path in humans. Saltarelli is now excited to join Biodexa. Chiesi itself may be about to become a strategic player in Lysosomal Storage with the approval of its Fabry asset in Europe and the US. Preclinical data for the xB3-Hunter program is expected in Q2. The world's largest healthcare company, J&J, is also investigating xB3. Daiichi also continues to be listed in BTI's financials.

Biodexa has a plan, the assets, the confidence, the backers, and the potential cash runway to execute on its immense potential. Again, Midatech's CEO stated he defies anyone to find a company of this size with the same opportunity set. J&J could validate Q-Sphera and xB3 this year. Is this a 'Saltarelli' on steriods? Biotech's deal of the year in the small cap space?

As Biodexa prepares to list on NASDAQ inflation has also dramatically moderated and NASDAQ is showing signs of potentially breaking out. With biotech having experienced its worst bear market in history it could have room to run. Biotech outperforms in a recession.